FDA Panel Endorses Expanded Approval For Boston Scientific CRT-Ds

Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) should be approved for use in some healthier heart failure patients, though not quite as many as the company initially proposed, an FDA advisory panel said March 18

More from Archive

More from Medtech Insight